To recover your password please fill in your email address
Please fill in below form to create an account with us
Title: A single-arm, open-label, phase II trial of entrectinib in patients with advanced tumours harbouring NTRK fusions or ROS1 gene rearrangements detected by comprehensive genomic profiling.
|
Trial Summary: |
The aim of this ASPiRATION and MoST substudy to assess the clinical activity of entrectinib in adult patients with advanced cancers harbouring NTRK or ROS1 gene alterations. |
|
Supported By: |
|
|
Eligibility: |
Adult patients with advanced cancers harbouring NTRK fusions or ROS1 gene rearrangements. NSCLC patients with ROS1 gene alterations must be FISH-negative, i.e. not eligible for reimbursed ROS1-targeted treatment. |
|
Registration ID: |
ACTRN12621000284864 |
|
Participation: |
National |
|
Status: |
Recruiting |
|
Activation Date: |
21/05/2021 |
|
Chairs: |
Dr Peey-Sei Kok, A/Prof Tom John, and Dr Subotheni Thavaneswaran |
|
Contact: |